AstraZeneca faces an uncertain future after Wainua's July 9 failure and a $34M kickback settlement on June 29. CEO Pascal Soriot's $80B 2030 sales target now hinges on out-innovating Chinese rivals, with a potential Bristol Myers merger adding another layer of complexity. Watch for White House's FDA Commissioner pick and further M&A news.